zacks.com · 23 jun

Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $32.96, moving 1.73% from the previous trading session.

gurufocus.com · 22 jun

A Look at Hims & Hers Health Inc (HIMS) After 5.4% Decline -- GF Value $38.53 vs Price $33.54

On June 22, 2026, Hims and Hers Health Inc (HIMS) shares fell 5.4% today, trading at $33.54. Over the past 52 weeks, the stock has ranged from a low of $13.74 to

zacks.com · 19 jun

Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

benzinga.com · 18 jun

Hims & Hers Stock Jumps After Barclays Raises Price Target

Hims & Hers Health Inc. (NYSE:HIMS) shares are climbing after Barclays reiterated its bullish stance and lifted its price target from $29 to $39. Here's what you need to know.

barrons.com · 18 jun

Living Longer Is Big Business. These Stocks Will Benefit.

TD Cowen analysts estimate that the total addressable market for longevity healthcare exceeds $250 billion.

seekingalpha.com · 18 jun

Hims & Hers: The Bull Case Remains Strong

Hims & Hers remains attractive at $33, supported by renewed Novo Nordisk partnership and unique access to patient demand. Despite weak Q1 2026 results—4% revenue growth, declining margins, and a net loss—international expansion and diversified categories are strengthening the long-term outlook. Management targets $6.5B+ revenue and $1.3B+ adjusted EBITDA by 2030, with valuation justified if retention and cross-sell improve.

zacks.com · 17 jun

Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $31.89, moving +1.33% from the previous trading session.

seekingalpha.com · 16 jun

Hims & Hers Enters A New Phase

The Novo Nordisk partnership transformed Hims & Hers Health, Inc. from a fringe obesity player into an official healthcare ecosystem participant. Short interest remains elevated near 30%-32% of the HIMS float, leaving roughly 63 million shares vulnerable to further covering. HIMS management targets at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030 through platform expansion.